Food and Drug Administration (FDA) Research 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.Current Role and Status for Intratumoral Injection Therapies in Metastatic Melanoma
Cancer J. 2024 Mar-Apr 01;30(2):108-112. doi: 10.1097/PPO.0000000000000709.ABSTRACTIntratumoral therapies represent a unique avenue for drug development in melanoma as patients often have accessible lesions that are particularly amenable to these approaches. In addition, a majority of intratumoral therapies have focused on stimulating antitumor immune responses, making them a particularly attractive option for use in melanoma. In this review, we describe applications for talimogene laherparepvec, a US Food and Drug Administration-approved intratumoral therapy in melanoma, as well as several classes of intratumoral therapie...
Source: Cancer Journal - March 25, 2024 Category: Cancer & Oncology Authors: Alexandra M Haugh Adil I Daud Source Type: research
Melanoma-Modern Treatment for Metastatic Melanoma
Cancer J. 2024 Mar-Apr 01;30(2):79-83. doi: 10.1097/PPO.0000000000000707.ABSTRACTTraditional chemotherapy has been ineffective in the treatment of metastatic melanoma. Until the use of checkpoint inhibitors, patients had very limited survival. Since the original US Food and Drug Administration approval of ipilimumab over a decade ago, the armamentarium of immunotherapeutic agents has expanded to include programmed cell death protein 1 and lymphocyte activation gene 3 antibodies, requiring a nuanced approach to the selection of frontline treatments, managing patients through recurrence and progression, and determining lengt...
Source: Cancer Journal - March 25, 2024 Category: Cancer & Oncology Authors: Maya Dimitrova Jeffrey Weber Source Type: research
Current Role and Status for Intratumoral Injection Therapies in Metastatic Melanoma
Cancer J. 2024 Mar-Apr 01;30(2):108-112. doi: 10.1097/PPO.0000000000000709.ABSTRACTIntratumoral therapies represent a unique avenue for drug development in melanoma as patients often have accessible lesions that are particularly amenable to these approaches. In addition, a majority of intratumoral therapies have focused on stimulating antitumor immune responses, making them a particularly attractive option for use in melanoma. In this review, we describe applications for talimogene laherparepvec, a US Food and Drug Administration-approved intratumoral therapy in melanoma, as well as several classes of intratumoral therapie...
Source: Cancer Journal - March 25, 2024 Category: Cancer & Oncology Authors: Alexandra M Haugh Adil I Daud Source Type: research
Melanoma-Modern Treatment for Metastatic Melanoma
Cancer J. 2024 Mar-Apr 01;30(2):79-83. doi: 10.1097/PPO.0000000000000707.ABSTRACTTraditional chemotherapy has been ineffective in the treatment of metastatic melanoma. Until the use of checkpoint inhibitors, patients had very limited survival. Since the original US Food and Drug Administration approval of ipilimumab over a decade ago, the armamentarium of immunotherapeutic agents has expanded to include programmed cell death protein 1 and lymphocyte activation gene 3 antibodies, requiring a nuanced approach to the selection of frontline treatments, managing patients through recurrence and progression, and determining lengt...
Source: Cancer Journal - March 25, 2024 Category: Cancer & Oncology Authors: Maya Dimitrova Jeffrey Weber Source Type: research
Current Role and Status for Intratumoral Injection Therapies in Metastatic Melanoma
Cancer J. 2024 Mar-Apr 01;30(2):108-112. doi: 10.1097/PPO.0000000000000709.ABSTRACTIntratumoral therapies represent a unique avenue for drug development in melanoma as patients often have accessible lesions that are particularly amenable to these approaches. In addition, a majority of intratumoral therapies have focused on stimulating antitumor immune responses, making them a particularly attractive option for use in melanoma. In this review, we describe applications for talimogene laherparepvec, a US Food and Drug Administration-approved intratumoral therapy in melanoma, as well as several classes of intratumoral therapie...
Source: Cancer Journal - March 25, 2024 Category: Cancer & Oncology Authors: Alexandra M Haugh Adil I Daud Source Type: research
Melanoma-Modern Treatment for Metastatic Melanoma
Cancer J. 2024 Mar-Apr 01;30(2):79-83. doi: 10.1097/PPO.0000000000000707.ABSTRACTTraditional chemotherapy has been ineffective in the treatment of metastatic melanoma. Until the use of checkpoint inhibitors, patients had very limited survival. Since the original US Food and Drug Administration approval of ipilimumab over a decade ago, the armamentarium of immunotherapeutic agents has expanded to include programmed cell death protein 1 and lymphocyte activation gene 3 antibodies, requiring a nuanced approach to the selection of frontline treatments, managing patients through recurrence and progression, and determining lengt...
Source: Cancer Journal - March 25, 2024 Category: Cancer & Oncology Authors: Maya Dimitrova Jeffrey Weber Source Type: research
Current Role and Status for Intratumoral Injection Therapies in Metastatic Melanoma
Cancer J. 2024 Mar-Apr 01;30(2):108-112. doi: 10.1097/PPO.0000000000000709.ABSTRACTIntratumoral therapies represent a unique avenue for drug development in melanoma as patients often have accessible lesions that are particularly amenable to these approaches. In addition, a majority of intratumoral therapies have focused on stimulating antitumor immune responses, making them a particularly attractive option for use in melanoma. In this review, we describe applications for talimogene laherparepvec, a US Food and Drug Administration-approved intratumoral therapy in melanoma, as well as several classes of intratumoral therapie...
Source: Cancer Journal - March 25, 2024 Category: Cancer & Oncology Authors: Alexandra M Haugh Adil I Daud Source Type: research
Melanoma-Modern Treatment for Metastatic Melanoma
Cancer J. 2024 Mar-Apr 01;30(2):79-83. doi: 10.1097/PPO.0000000000000707.ABSTRACTTraditional chemotherapy has been ineffective in the treatment of metastatic melanoma. Until the use of checkpoint inhibitors, patients had very limited survival. Since the original US Food and Drug Administration approval of ipilimumab over a decade ago, the armamentarium of immunotherapeutic agents has expanded to include programmed cell death protein 1 and lymphocyte activation gene 3 antibodies, requiring a nuanced approach to the selection of frontline treatments, managing patients through recurrence and progression, and determining lengt...
Source: Cancer Journal - March 25, 2024 Category: Cancer & Oncology Authors: Maya Dimitrova Jeffrey Weber Source Type: research
Current Role and Status for Intratumoral Injection Therapies in Metastatic Melanoma
Cancer J. 2024 Mar-Apr 01;30(2):108-112. doi: 10.1097/PPO.0000000000000709.ABSTRACTIntratumoral therapies represent a unique avenue for drug development in melanoma as patients often have accessible lesions that are particularly amenable to these approaches. In addition, a majority of intratumoral therapies have focused on stimulating antitumor immune responses, making them a particularly attractive option for use in melanoma. In this review, we describe applications for talimogene laherparepvec, a US Food and Drug Administration-approved intratumoral therapy in melanoma, as well as several classes of intratumoral therapie...
Source: Cancer Journal - March 25, 2024 Category: Cancer & Oncology Authors: Alexandra M Haugh Adil I Daud Source Type: research
Melanoma-Modern Treatment for Metastatic Melanoma
Cancer J. 2024 Mar-Apr 01;30(2):79-83. doi: 10.1097/PPO.0000000000000707.ABSTRACTTraditional chemotherapy has been ineffective in the treatment of metastatic melanoma. Until the use of checkpoint inhibitors, patients had very limited survival. Since the original US Food and Drug Administration approval of ipilimumab over a decade ago, the armamentarium of immunotherapeutic agents has expanded to include programmed cell death protein 1 and lymphocyte activation gene 3 antibodies, requiring a nuanced approach to the selection of frontline treatments, managing patients through recurrence and progression, and determining lengt...
Source: Cancer Journal - March 25, 2024 Category: Cancer & Oncology Authors: Maya Dimitrova Jeffrey Weber Source Type: research
Current Role and Status for Intratumoral Injection Therapies in Metastatic Melanoma
Cancer J. 2024 Mar-Apr 01;30(2):108-112. doi: 10.1097/PPO.0000000000000709.ABSTRACTIntratumoral therapies represent a unique avenue for drug development in melanoma as patients often have accessible lesions that are particularly amenable to these approaches. In addition, a majority of intratumoral therapies have focused on stimulating antitumor immune responses, making them a particularly attractive option for use in melanoma. In this review, we describe applications for talimogene laherparepvec, a US Food and Drug Administration-approved intratumoral therapy in melanoma, as well as several classes of intratumoral therapie...
Source: Cancer Journal - March 25, 2024 Category: Cancer & Oncology Authors: Alexandra M Haugh Adil I Daud Source Type: research
Melanoma-Modern Treatment for Metastatic Melanoma
Cancer J. 2024 Mar-Apr 01;30(2):79-83. doi: 10.1097/PPO.0000000000000707.ABSTRACTTraditional chemotherapy has been ineffective in the treatment of metastatic melanoma. Until the use of checkpoint inhibitors, patients had very limited survival. Since the original US Food and Drug Administration approval of ipilimumab over a decade ago, the armamentarium of immunotherapeutic agents has expanded to include programmed cell death protein 1 and lymphocyte activation gene 3 antibodies, requiring a nuanced approach to the selection of frontline treatments, managing patients through recurrence and progression, and determining lengt...
Source: Cancer Journal - March 25, 2024 Category: Cancer & Oncology Authors: Maya Dimitrova Jeffrey Weber Source Type: research
Current Role and Status for Intratumoral Injection Therapies in Metastatic Melanoma
Cancer J. 2024 Mar-Apr 01;30(2):108-112. doi: 10.1097/PPO.0000000000000709.ABSTRACTIntratumoral therapies represent a unique avenue for drug development in melanoma as patients often have accessible lesions that are particularly amenable to these approaches. In addition, a majority of intratumoral therapies have focused on stimulating antitumor immune responses, making them a particularly attractive option for use in melanoma. In this review, we describe applications for talimogene laherparepvec, a US Food and Drug Administration-approved intratumoral therapy in melanoma, as well as several classes of intratumoral therapie...
Source: Cancer Journal - March 25, 2024 Category: Cancer & Oncology Authors: Alexandra M Haugh Adil I Daud Source Type: research
Melanoma-Modern Treatment for Metastatic Melanoma
Cancer J. 2024 Mar-Apr 01;30(2):79-83. doi: 10.1097/PPO.0000000000000707.ABSTRACTTraditional chemotherapy has been ineffective in the treatment of metastatic melanoma. Until the use of checkpoint inhibitors, patients had very limited survival. Since the original US Food and Drug Administration approval of ipilimumab over a decade ago, the armamentarium of immunotherapeutic agents has expanded to include programmed cell death protein 1 and lymphocyte activation gene 3 antibodies, requiring a nuanced approach to the selection of frontline treatments, managing patients through recurrence and progression, and determining lengt...
Source: Cancer Journal - March 25, 2024 Category: Cancer & Oncology Authors: Maya Dimitrova Jeffrey Weber Source Type: research
Current Role and Status for Intratumoral Injection Therapies in Metastatic Melanoma
Cancer J. 2024 Mar-Apr 01;30(2):108-112. doi: 10.1097/PPO.0000000000000709.ABSTRACTIntratumoral therapies represent a unique avenue for drug development in melanoma as patients often have accessible lesions that are particularly amenable to these approaches. In addition, a majority of intratumoral therapies have focused on stimulating antitumor immune responses, making them a particularly attractive option for use in melanoma. In this review, we describe applications for talimogene laherparepvec, a US Food and Drug Administration-approved intratumoral therapy in melanoma, as well as several classes of intratumoral therapie...
Source: Cancer Journal - March 25, 2024 Category: Cancer & Oncology Authors: Alexandra M Haugh Adil I Daud Source Type: research
